Professional Documents
Culture Documents
NIM : 1608010041
THERAPY WORKSHEET
Citation: Grosser D, Smith B. Low-dose budesonide improved asthma control in mild asthma; adding
formeterol improved control in corticosteroid-treated patients. ACP journal club. 2002 Jul 1;137(1):19-.
Was the assignment of patients to treatments Ya. Penelitian ini menggunakan sampel acak, dan
randomised? dirahasiakan (Pasien, Klinisi/Dokter, Pengumpul
Was the randomisation list concealed? data, Penilai hasil, Data analis, dan Komite
Pemantauan).
Was follow-up of patients sufficiently long and Ya. Alokasi waktu follow up pasien cukup, yaitu
complete? selama 1 tahun.
Were all patients analysed in the groups to which Ya. Tetapi pada masing masing grup di ketahui
they were randomised? bahwa terdapat karakteristik yang sama. Grup A
terdiri dari pasien yang tidak pernah menggunakan
steroid, sisanya adalah pasien yang belum
menginhalasi steroid selama > 3 bulan, sedangkan
Grup B berisi pasien yang menggunakan steroid
inhalasi selama lebih dari 3 bulan.
Were patients and clinicians kept “blind” to Ya. Semua terapi dirahasiakan baik dari Pasien,
treatment? Klinisi/Dokter, Pengumpul data, Penilai hasil, Data
analis, dan Komite Pemantauan.
Were the groups treated equally, apart from the Ya. Selain karena alasan percobaan yang
experimental treatment? mengharuskan kelompok A dan B mendapat terapi
berbeda, kedua kelompok mendapat perlakuan
yang sama.
Were the groups similar at the start of the trial? Tidak. Pada awal uji coba, kedua kelompok sudah
dipisahkan menurut karakteristik tertentu (yaitu
apakah pasien menggunakan kortikosteroid
inhalasi atau tidak dan waktu penggunaannya) lalu
pada tahap percobaan awal, di 4 minggu pertama
kedua grup mendapat perlakuan berbeda, grup A
mendapat placebo sedangkan grup B mendapat
budesonide 100 µg 2 kali sehari.
YOUR CALCULATIONS
Relative risk Absolute risk Number
reduction reduction needed to
(RRR) (ARR) treat (NNT)
CER EER CER – EER CER-EER 1/ARR
CER
95% CI
Can you apply this valid, important evidence about therapy in caring for your
patient?
Do these results apply to your patient?
Is your patient so different from those in
the study that its results cannot apply?
Is the treatment feasible in your setting?
What are your patient’s potential benefits and harms from the therapy?
Method I: f Risk of the outcome in your patient,
relative to patients in the trial.
Expressed as a decimal: ______
NNT/f = ______ / ______ = ______
(NNT for patients like yours)
Method II: 1/(PEER x RRR) Your patient’s expected event rate if they
received the control treatment (PEER)
= ______
1/(PEERxRRR) = 1/________ = ______
(NNT for patients like yours)
Are your patient’s values and preferences satisfied by the regimen and its
consequences?
Do your patient and you have a clear
assessment of their values and
preferences?
Are they met by this regimen and its
consequences?
Additional notes: